USP13决定了在扩散性大B细胞淋巴瘤 (DLBCL) 中的Ran周转率和对铁亡的脆弱性
Xuan Qiao1, Xingmeng Yang1, Yuanhao Diao1
1College of Pharmaceutical Sciences, Southwest University, Chongqing, China.
Cell death & disease
|November 28, 2025
概括
USP13 deubiquitinates 在扩散性大B细胞淋巴瘤 (DLBCL) 中运行,一种致命的癌症. 用Spautin-1抑制USP13与化疗协同作用,诱导铁,为DLBCL患者提供新的治疗希望.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种流行和侵略性的B细胞恶性瘤,复发率高,治疗选择有限.
- 脱基酶 (DUBs) 通过稳定上蛋白质,在癌症中发挥关键作用,使其成为潜在的治疗点.
研究的目的:
- 识别和描述涉及DLBCL病原体的新型DUB.
- 研究USP13在DLBCL中的作用及其作为治疗点的潜力.
主要方法:
- 通过LC-MS/MS和AlphaFold3建模来识别USP13基质和相互作用.
- 药物抑制 (Spautin-1) 和USP13.的基因操纵
- 用RNA测序来识别受USP13抑制影响的下游途径.
- 在体外和体内实验,以评估治疗疗效和机制.
主要成果:
- USP13被确定为DLBCL中的过度表达的DUB,对疾病的发病具有关键作用.
- USP13二维基化Ran GTPase,调节其稳定性和无处不在.
- 抑制USP13会影响NF-κB和Notch通路,这与化学抵抗有关.
- Spautin-1与多克索鲁比或环胺协同作用,以诱导DLBCL中的铁亡,对器官有最小的毒性.
结论:
- 在DLBCL中,USP13通过对Ran.Ran.Ran进行二基因化发挥着重要作用.
- 使用Spautin-1和标准化疗 (多克索鲁比或环胺) 的联合治疗显示出通过诱导铁死来治疗DLBCL的前景.
- 这种组合方法为对抗DLBCL提供了潜在的新疗法策略.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
01:23Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
01:31The Intrinsic Apoptotic Pathway
8.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.2K
01:31Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K
02:04Covalently Linked Protein Regulators
8.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.6K
01:42Directionality of Nuclear Transport
4.5K
Ras-related nuclear protein or Ran is a small G protein that cycles between its GTP and GDP bound states. Ran specific regulators, a Ran GTPase Activating Protein or RanGAP present in the cytosol and a Ran guanine nucleotide exchange factor or RanGEF present inside the nucleus regulate GTP/GDP exchange. A high concentration of GTP inside the cells, in addition to this asymmetric distribution of Ran-specific regulators, leads to a higher RanGTP concentration inside the nucleus. This...
4.5K